For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Kaketsuken Faces 110-Day Biz Suspension, Urged to Dissolve as Legal Entity
January 8, 2016
- Careful Administration Re-stressed for Inavir, Relenza in Dairy-Sensitive Patients: Safety Bulletin
January 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for December 2015
January 8, 2016
- Shipment of Some Lots of Kaketsuken’s Kenketsu Globulin OK’ed
January 7, 2016
- Health Policy Bureau’s FY2016 Draft Budget Earmarks 5.7 Billion Yen to Promote Clinical Research
January 5, 2016
- Health Service Bureau Increases Budgets for Measures against Hepatitis, Infectious Diseases: FY2016 Draft Budget
January 5, 2016
- Gist of FY2016 Drug Pricing Reform
December 25, 2015
- Chuikyo OKs Outline of FY2016 Drug Pricing Reform
December 25, 2015
- 130 Million Yen Earmarked to Boost PMDA Staffers for Accelerating Review: FY2016 Budget
December 25, 2015
- MHLW Looked at Innovativeness, Seriousness of Target Disease to Select Sakigake Products
December 25, 2015
- MHLW Launches Confab to Shore Up Healthcare Startup Sector
December 25, 2015
- Drug Price Cuts to Save 174.9 Billion Yen in State Coffers: MOF
December 25, 2015
- FY2016 Draft Budget Includes 82.5 Bil. Yen to Promote Creation of Innovative New Drugs and Medical Devices
December 25, 2015
- AMED-Led Screening Consortium Gets Underway with 22 Japanese Makers
December 24, 2015
- Plavix, 15 Other Brands to Lose Premiums on Generic, Biosimilar Entries; Re-Pricing Could Deal Another Blow
December 24, 2015
- MHLW OKs Add’l Indications for Remicade, Other Drugs
December 22, 2015
- Drug Prices to Be Pared 7.8% If Re-Pricing, Z2, Generic Price Cuts Included
December 22, 2015
- 3.6 Billion Yen in FY2015 Extra Budget to Go to IFN-Free Hep C Therapies
December 21, 2015
- Japan, India Sign Memorandum for Regulatory Affairs
December 21, 2015
- MHLW Grants Orphan Drug Designation for Sakigake Product Sirolimus, Others
December 21, 2015
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…